Type A Meeting

Type A meetings are those meetings that are necessary for an otherwise stalled drug development program to proceed (i.e., a “critical path” meeting) or to address an important safety issue. Post-action meetings requested within three months after an FDA regulatory action other than approval (i.e., issuance of a complete response letter) will also generally be considered Type A meetings.